Australia's most trusted
source of pharma news
Posted 8 April 2026 AM
As Australia settled into the Easter Long Weekend Trump threw a fox into the Easter Bunny hutch with a proclamation revisiting pharmaceutical tariffs. This is likely to affect the pharmaceutical companies operating in Australia far more than our citizens.
Local reporting paid scant attention to the tariffs also being placed on active pharmaceutical ingredients (APIs), which the proclamation makes clear are considered by the US Administration as just as important to manufacture within the US as the finished pharmaceutical products.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.